SHR-1210

camrelizumab · Jiangsu Hengrui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

52 regulatory and trial events tracked for SHR-1210, covering 2017-06-06 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) [Phase 2]